About: Macrolides in critically ill patients with Middle East Respiratory Syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Macrolides in critically ill patients with Middle East Respiratory Syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Macrolides in critically ill patients with Middle East Respiratory Syndrome
Creator	Balkhy, Hanan Fowler, Robert Alraddadi, Basem Al-Omari, Awad Al-Hameed, Fahad Almotairi, Abdullah Jose, Jesna Kharaba, Ayman Mandourah, Yasser Qushmaq, Ismael Shalhoub, Sarah Hayden, Frederick Merson, Laura Arabi, Yaseen Al Harthy, Abdulrahman Mady, Ahmed Abdulmomen, Ahmed Al Khatib, Kasim Al-Raddadi, Rajaa Solaiman, Othman Sindi, Anees Dabbagh, Tarek Ragab, Ahmad Al-Aithan, Abdulsalam Arabia, Arabia, Saudi Deeb, Ahmad Riyadh, Saudi Ahsa, Al Almekhlafi, Ghaleb Health Affairs, Guard
Source	Elsevier; Medline; PMC
abstract	OBJECTIVES: Macrolides have been reported to be associated with improved outcomes in patients with viral pneumonia related to influenza and other viruses, possibly because of their immune-modulatory effects. Macrolides have frequently been used in patients with Middle East Respiratory Syndrome (MERS). This study investigated the association of macrolides with 90-day mortality and MERS coronavirus (CoV) RNA clearance in critically ill patients with MERS. METHODS: This retrospective analysis of a multicenter cohort database included 14 tertiary-care hospitals in five cities in Saudi Arabia. Multivariate logistic-regression analysis was used to determine the association of macrolide therapy with 90-day mortality, and the Cox-proportional hazard model to determine the association of macrolide therapy with MERS-CoV RNA clearance. RESULTS: Of 349 critically ill MERS patients, 136 (39%) received macrolide therapy. Azithromycin was most commonly used (97/136; 71.3%). Macrolide therapy was commonly started before the patient arrived in the intensive care unit (ICU) (51/136; 37.5%), or on day1 in ICU (53/136; 39%). On admission to ICU, the baseline characteristics of patients who received and did not receive macrolides were similar, including demographic data and sequential organ failure assessment score. However, patients who received macrolides were more likely to be admitted with community-acquired MERS (P = 0.02). Macrolide therapy was not independently associated with a significant difference in 90-day mortality (adjusted odds ratio [OR]: 0.84; 95% confidence interval [CI] :0.47–1.51; P = 0.56) or MERS-CoV RNA clearance (adjusted HR: 0.88; 95% CI:0.47–1.64; P = 0.68). CONCLUSIONS: These findings indicate that macrolide therapy is not associated with a reduction in 90-day mortality or improvement in MERS-CoV RNA clearance.
has issue date	2019-01-25(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2019.01.041
bibo:pmid	30690213
has license	no-cc
sha1sum (hex)	bae0b01b4d54ed9f2a304ada45d10d4738688bf9
schema:url	https://doi.org/10.1016/j.ijid.2019.01.041
resource representing a document's title	Macrolides in critically ill patients with Middle East Respiratory Syndrome
has PubMed Central identifier	PMC7110878
has PubMed identifier	30690213
schema:publication	Int J Infect Dis
resource representing a document's body	covid:bae0b01b4d54ed9f2a304ada45d10d4738688bf9#body_text
is schema:about of	named entity 'patients' named entity 'MACROLIDES' named entity 'PATIENTS' named entity 'MIDDLE EAST RESPIRATORY SYNDROME' named entity 'CRITICALLY ILL' named entity 'critically ill patients' named entity 'RCT' named entity 'RNA' named entity 'malignancy' named entity 'macrolide' named entity 'MERS' named entity 'azithromycin' named entity 'MERS' named entity 'RCT' named entity 'legionella' named entity 'immunopathologic' named entity 'IL-4' named entity 'azithromycin' named entity 'bronchiolitis' named entity 'macrolides' named entity 'Saudi Arabia' named entity 'plasma' named entity 'MERS' named entity 'RCT' named entity 'MERS-CoV' named entity 'ICU' named entity 'survivorship bias' named entity 'ICU' named entity 'inflammatory responses' named entity 'MERS-CoV' named entity 'monotherapy' named entity 'prokinetic agent' named entity 'ICU' named entity '95% CI' named entity 'clarithromycin' named entity 'physiological parameters' named entity 'chlamydia' named entity 'parainfluenza' named entity 'critically ill patients' named entity 'intubation' named entity 'clarithromycin' named entity 'macrolide' named entity 'RNA' named entity 'independent variable' named entity 'ICU' named entity 'macrolides' named entity 'oseltamivir' named entity 'community-acquired' named entity 'rhinovirus' named entity 'ventilator' named entity 'macrolide'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software